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Abstract

As the second leading cause of death in 2016, cancer is one of the most serious diseases facing
the world today. T cell therapy is a current area of research attempting to address the disease
with two primary division: CAR-T and TCR-T cell therapy. The immune system naturally
produces T lymphocytes to aid in the recognition and removal of cells infected with viruses or
transformed into cancer. Under normal circumstances, T lymphocytes identify and destroy
cancerous cells; however, some cancerous cell types can evade this system. With the use of
genetic editing technology, T lymphocytes can gain the ability to recognize these evasive
cancers. The editing process is known as T cell therapy.
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T Cell Therapy: Underlying Mechanisms and Current Advancements
Discussion
Overview
Cancer is one of the most serious diseases facing the United States today (Siegel et al.,
2016). In 2016, it was the second leading cause of death behind heart disease with an average of
4,600 new diagnoses daily. With the severity of the disease, new research is continually being
conducted to better comprehend its molecular mechanisms. Great strides have been made in the
reduction of cancer deaths; however, improvements can still be made in many cancer types. One
avenue currently being evaluated for this is T cell therapy. To better understand how this
treatment interacts with cancerous cells, a base understanding of cancer will be set first.
Hallmarks of Cancer
In their discussion on cancer, Hanahan & Weinberg (2011) set out six distinctive
hallmarks of cells that make up these growths. Essentially, cancerous cells begin as normal
functioning cells; however, as they mutate, they gradually gain each of these six hallmarks.
Arguably, at their most base level, cancerous cells “sustain chronic proliferation” or the tendency
to grow uncontrollably without accountability (Hanahan & Weinberg, 2011, p. 646). If these
cells live, they will continue to divide without check, spreading well beyond their intending
plane of living. They accomplish this by “evading growth suppressors,” another hallmark of the
transformation (Hanahan & Weinberg, 2011, p. 648). Under normal conditions, cells exhibiting
uncontrolled growth would be rendered inert and killed by various cellular mechanisms
regulating tumor growth such as the RB protein. This protein “integrates signals from diverse
extracellular and intracellular sources and, in response, decides whether or not a cell should
proceed through its growth-and-division cycle,” (Hanahan & Weinberg, 2011, p. 648).
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Additionally, cancerous cells possess the ability to bypass the replicative limitations imposed on
normally functioning, non-stem cells. While most normally replicating cells can only replicate
for a few generations before dying, cancerous cells have bypassed this inhibition to replicate
indefinitely. They also induce angiogenesis to create extra blood vessels to support the growing
mass of cells. Going further, cancerous cells generate the ability to invade neighboring cell types
and spread to the rest of the body, inducing metastasis. Finally, these cells also resist apoptosis.
Through both extrinsic and intrinsic signaling pathways, programmed cell death can be induced
in damaged cells. T lymphocytes naturally survey the environment for altered-self or damaged
cells requiring the induction of this process for the maintenance of homeostasis. Unfortunately,
evasive cancer types avoid the mechanism to further promote survival. By altering the T
lymphocytes’ natural recognition and killing ability, T cell therapy attempts to address the
problem of evasive cancerous cells.
T lymphocytes
One of the functions of T lymphocytes is to meditate the killing of damaged cells via the
humoral and cellular immune responses (Chaplin, 2010). There are a variety of subsets that
facilitate this function. The two main varieties are cytotoxic (Tc) and helper (Th) T lymphocytes,
the first serving to scan for damaged or altered-self cells and the second as controller cells
granting permission for activation of cytotoxic and B lymphocytes. This is accomplished through
interactions between the lymphocytes’ T cell receptor (TCR) and surface markers on surrounding
cells. To determine if a peripheral cell is damaged or altered, the TCR interacts with cell-surface
glycoproteins known as major histocompatibility molecules (MHCs). MHCs present peptide
antigens processed from both internal and external pathways, known as endogenous and
exogenous respectively. For a TCR to interact with an MHC and its presented antigen, it must
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also possess surface proteins known as clusters of differentiation (CDs). A wide variety of CDs
are observed across the body that serve a variety of functions; however, central to T cell therapy
are two: CD4 and CD8.
Tc and Th cells are differentiated mainly on whether they are CD4+ or CD8+ as they are
central to function (Chaplin, 2010). Cytotoxic cells express CD8 while helper cells express CD4.
CD4 and CD8 determine T lymphocyte function by limiting interactions to specific MHCs and
activating different signaling pathways. There are two main classes of MHC molecules: I and II.
MHC class I presents antigens processed endogenously to CD8+ T cells while class II presents
exogenously processed antigens to CD4. By interacting with antigens processed extracellularly,
Th cells work to modulate the humoral and cellular response to potentially pathogenic organisms
while also alerting Tc cells to potential threats. Contrarily, Tc cells function by killing damaged or
infected cells as they primarily interact with antigens originating from intracellular products.
Through the natural endogenous processing system, intracellular products are broken down into
small peptide fragments for presentation on MHC class 1 molecules to CD8+ T lymphocytes.
Tc Function
Tc lymphocytes play an important role in the immune system by responding to
endogenous antigens (Chaplin, 2010). Nearly every cell in the body expresses MHC class I
molecules for the expression of endogenous antigens. The intracellular antigens expressed on
these MHCs originate primarily from expired cellular products. Through the processes of
negative selection and tolerance, Tc cells are unable to bind self-antigens, thus any cell
expressing them is passed over preventing the immune system from attacking normally
functioning cells. Due to this system of endogenous antigen presentation, Tc lymphocytes are
also able to catch viral or altered-self products of these cells. Upon identifying such non-self
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products, apoptosis can be induced in the target cell through cytokine signaling or ligand
binding. This is a spontaneous and natural process constantly occurring in the body as T
lymphocytes pass tissues through normal bodily function.
Negative Selection and Tolerance
To properly discriminate between self and non-self antigens, T lymphocytes undergo a
thorough selection process during development followed by tolerance programming in peripheral
tissues (Passos et al., 2017). After initial differentiation in the bone marrow, T lymphocytes are
sent to the thymus to undergo development. Here, they are selected based on their antigen
recognition. Generally, if they recognize a self antigen, they are killed; however, if they
recognize a non-self antigen, they are allowed to survive. The process occurs in two steps:
positive and negative selection. During negative selection, specialized medullary thymic
epithelial cells (mTECs) expressing the autoimmune regulator (Aire) gene present self-antigens
to naïve T lymphocytes. The Aire gene allows mTECs to display antigens from tissues found
throughout the body. These cells effectively serve as a trial run for naïve T lymphocytes. If the T
lymphocytes were to react with the repertoire of self antigens displayed on these cells, an
apoptotic signal would be induced, promoting cell death in a process known as clonal deletion.
Functionally, this serves the body well, because if numerous self-reactive T cells were allowed to
mature, an autoimmune reaction would ensue.
Unfortunately, negative selection is not a perfect process as not all self antigens are
presented (Redmond et al., 2008). This allows some self-reactive T cells to escape. To atone for
these errors, self antigens are again presented to lymphocytes in secondary lymphoid tissues via
APC cross-presentation and regulatory T cells (Treg) (Beissert et al., 2006). If T cells interact
with these antigens, peripheral tolerance mechanisms are activated that serve to either induce
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anergy or apoptosis in the self-reactive cells. For example, through interactions with APCs via
cytotoxic T lymphocyte-associated antigen – 4 (CTLA-4), Treg cells can impede APC production of tryptophan, a
proliferative stimulus for Tc cells, to inhibit Tc cell activation. This process presents a roadblock
to a T lymphocyte’s ability to fight evasive cancer types.
Tc Cell Limitations and Cancer
Largely, CD8+ Tc cells function to destroy self cells that have been infected or altered so
that they no longer serve their original bodily function. They screen for such cells by examining
antigens presented on MHC class 1 molecules. Non-self antigens presented on these cells’ MHCs
mark them for death based on the programming of central and peripheral tolerance. Through this
system, many diseases are fought by Tc cells; unfortunately, diseases in which the damaged cell
continues presenting normal antigens are not as easily detected. Many proliferative diseases that
produce tumors such as cancer fall under this category as they suppress the expression of tumor
markers on MHC class 1 molecules. Therefore, normally reproducing Tc cells are largely unable
to destroy cancerous growths.
Additionally, these tissues are often surrounded by an abundant number of
immunosuppressive cells such as regulatory T lymphocytes and M2 macrophages in a dense
fibrous matrix (Zhao & Cao, 2019). The dense matrix impedes the ability of the lymphocytes to
access the rampantly dividing cells. Meanwhile, immunosuppressive cells can inhibit T
lymphocytes by binding to negative regulatory ligands found on their surface such as cytotoxic T
lymphocyte antigen-4 (CTLA-4) (Smith-Garvin et al., 2009). CTLA-4 is an important inhibitory
receptor found on the surface of T lymphocytes important in self-tolerance. An additional
inhibitory receptor found on T lymphocytes is the programmed death-1 (PD-1) receptor. Both
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these receptors are targeted by the immunosuppressive matrix surrounding dense tumors to limit
the expansion and activation of T lymphocytes. Also, suppressive cytokines are released to
further limit the activity of these cells such as IL-10. Finally, the dense matrix has been found to
induce lymphocyte exhaustion due to a lack of essential amino acids, low oxygen concentration,
and high acidity (Zhao & Cao, 2019). Taken together, the environment surrounding solid tumors
specifically targets the proliferative ability and activation of T lymphocytes through cytokine
secretion, inhibitor binding, and nutrient deprivation.
T Cell Therapy
Due to the body’s inability to fight some transformed cells, numerous treatments have
been devised to address the disease. To do so, the treatments must first identify and then exploit
physiological differences between normal and cancerous cells. Some of the most common such
as chemotherapy and radiation therapy are devised to target cancer’s hallmark of chronic
proliferation. The majority of normally functioning cells in the body do not proliferate
continually; therefore, these chemicals can be used to destroy cancer while leaving most healthy
cells unaffected. Unfortunately, cells that multiply quickly under normal circumstances are also
killed. Subsequently, these therapies have a high toll on the body, killing cells such as hair
follicles and many activating immune cells limiting clonal expansion. To fully eradicate the
disease, surgery is often used to remove the weakened growths.
While this strategy is effective for some cancers, many types remain unaffected by it.
Additionally, the effects it has on the body are destructive. Therefore, new treatments are
continually being developed to target other hallmarks. T cell therapy is one such treatment as it
attempts to address the roadblocks keeping T lymphocytes from destroying cancerous cells (Chi
et al., 2016). First, through the genetic altering technology of CRISPR/Cas9 or retroviral vectors,
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TCR genes can be edited to code for a binding pocket that recognizes specific cancerous
antigens, programming the T lymphocytes to target these cells (Milone & O’Doherty, 2018).
This binding pocket is composed of two polypeptide chains, which both contribute to the
specificity of the antigen binding domain (Roth, 2014). The chains responsible for the binding
domain are encoded by exons composed of variable (V), diversity (D), and joining (J) regions.
These are normally assembled through the process of V(D)J recombination. During development
in the thymus, these regions are rearranged by ligating random regions sequentially from V to D
to J. This generates variability in the antigen binding domain. Further variability is also added by
random addition and deletion of the nucleotides in the junctions between regions. The result of
this variability is that each antigen binding domain binds one specific antigen. In T cell therapy,
this process is altered by addition of specific genes encoding for a specific binding pocket.
Finally, these altered cells are aided in accessing the diseased tissue by editing additional
genes that promote survival and cell penetration (Zhao & Cao, 2019). If fully developed, the
technique could attack cancer while leaving the rest of the body untouched. Improvements must
be made; however, strides are routinely being made to further progress the treatment.
CRISPR/Cas9
The origins of the CRISPR/Cas9 system are found in bacteria as a defense mechanism
from foreign, invading genetic material such as viral DNA and plasmids (Ren & Zhao, 2017).
Viruses routinely attempt to take over bacterial, host machinery to replicate progeny by inserting
their genetic material for insertion into the host genome. Undefended, the host cell would be
destroyed. The CRISPR/Cas9 system is used to fight this attack by recognizing foreign genetic
information and marking it for degradation. Essentially, the system is divided into two separate
components forming a complex: a CRISPR DNA library and a Cas9 endonuclease. If the cell
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recognizes foreign, genetic material, it is destroyed while a copy is created and inserted into a
DNA library. After addition to the library, CRISPR RNA (crRNA) is transcribed from the stored
DNA sequence to bind the genetic material if infected again. If the bacterium is again targeted,
the crRNA serves as a guide RNA for Cas9. Upon recognition, the crRNA binds the invading
genetic material, complexing with and activating Cas9. This triggers the endonuclease to cleave
the viral genetic material.
This defense system can be utilized to induce exact edits to genetic information (Chi et
al., 2016). By leading Cas9 to specific sites, researchers have been able to induce DSBs at
precise locations in targeted DNA. To begin, guide RNAs engineered to pair with specific DNA
sequences are produced to bypass the use of crRNA. This guide RNA complexes with the Cas9
endonuclease to create double-stranded breaks (DSBs). Meanwhile, a significant amount of
donor sequence is introduced to the break site (Zhan et al., 2018). The donor sequence possesses
blunt ends matching that of the DSB to encourage cell-mediated homology-directed repair
(HDR). The process ends with the permanent insertion of the new sequence into the host genome
to direct downstream transcription. While effective, this method of gene editing is not commonly
utilized in T cell therapy.
Retroviral Vectors
An alternate avenue of insertion of donor DNA can be achieved using retroviral vectors
(Milone & O’Doherty, 2018). These vectors are created from genetically altered retroviruses.
Normally these viruses survive by integrating their genetic information into the host genome.
This is accomplished through viral integration. Under normal conditions, the mature retrovirus
begins its life cycle after infecting the host. At this stage, viral proteins and genetic material are
unloaded into the host cell. The viral proteins proceed to form an integration complex with a
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primary component known as viral integrase (IN). IN prepares the donor information via 3 strand
cleavage with the genetic information to form the reverse transcription complex (RTC). This
complex converts the RNA into viral DNA in the process of reverse transcription. Additionally,
it aids in the process of inserting the viral DNA into the host genome. Upon insertion, the host
machinery transcribes the viral information into viral particles to produce viral progeny.
This process can be harnessed to engineer the genetic information of T lymphocytes by
inserting donor DNA encoding either an edited receptor or additional binding components into
the cell’s genome (Milone & O’Doherty, 2018). To begin, the subclass of retrovirus is selected
as each possesses different insertion preferences. Unfortunately, the exact point of insertion is
difficult to control. Each vector possesses different affinities for insertion sites; however, the
points of insertion are still variable (Ren & Zhao, 2017). A way to increase site specificity is by
incorporating the CRISPR system as a guide for the viral machinery. This technique allows the
viral genetic information to gain access to the cell through retrovirus machinery while also
allowing site specificity through the CRSIPR-Cas9 system.
In addition, steps are taken to decrease the virulence ability of the retrovirus (Ren &
Zhao, 2017). Viral vectors are crippled to remove their ability to replicate on their own. If the
vector were to retain its replicative ability, it would hijack the cell for creation of progeny. To do
this, specific virulence genes are removed while additional viral genes are separated into separate
plasmids. The donor sequences are then packaged and added to the retrovirus. Once
accomplished, the viral vector is no more than a delivery agent incapable of self-replication.
From this point, the targeted cell is transformed with the vector to accomplish genetic editing.
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CAR-T and TCR-T Cell Therapy
T cell therapy researchers use genetic editing technology to genetically alter the binding
and activation components of T lymphocytes (Duong et al., 2019). They do this in one of two
ways. Either the TCR is altered to create a binding pocket specific to cancerous antigens or an
additional binding component known as a chimeric antigen receptor (CAR) is added to the
binding repertoire. Both techniques alter the binding capability of the cell; however, they do so
in varying ways.
TCR-T Cell Therapy
The first editing technique, TCR-T cell therapy, originated from an experiment by
Bluthmann et al. (1988) in which TCR genes were transfected from one T cell to another giving
them identical binding capabilities. This technique was adapted to alter TCR genes to bind
specific antigens presented by cancerous cells (Zhao & Cao, 2019). The first step is to identify
antigens presented specifically by the cancerous growth being targeted. According to Rath &
Arber, four criteria are required for successful antigen selection (2020). First, the antigen must be
selectively expressed on tumor cells. It must also have a low or negligible expression on healthy
cells. After this, it must possess sufficient immunogenicity to generate an immune response
against it. Finally, the tumor’s survival must rely on the antigen’s presentation. Once an antigen
fitting these criteria is discovered, its structure is analyzed to determine the structure of the
required TCR binding pocket necessary for high-affinity binding to both MHC and antigen
(Zhao & Cao, 2019). The complementarity determining regions (CDRs) of the variable amino
acid chains in the TCR are altered to bind and generate an activation signal in the T lymphocyte
(Rath & Arber, 2020). To accomplish this, live, naïve T lymphocytes are removed ex vivo for
genetic editing (Zhao & Cao, 2019). While gene editing could be accomplished in vivo, extreme
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risks accompany such a technique. Such risks include generating T lymphocytes with
autoimmune tendencies. For example, through improper editing, the effects of negative selection
and peripheral tolerance could be overridden. As previously stated, T lymphocytes with high
affinity for self antigens are destroyed to decrease the risk for immune targeting of healthy
bodily cells. If TCR therapy results in lymphocytes with affinity for healthy cells, the targeting
of evasive cancer species would not only fail but cause potentially lethal side effects. Therefore,
the cells are removed for editing outside the body. Once removed, genetic loci are targeted in the
host genome by genetic editing mechanisms. Insertion of the DNA donor sequence coding for
the new binding pocket follows. The engineered T lymphocytes are tested for successful
conversion then reinstituted into the body near the site of cancerous activity to induce cellular
death in the diseased cells.
Clinical Manifestations
Successful applications of this technique have been shown in numerous different settings.
One example is found in a study conducted by Rapaport et al. in which TCR engineered T
lymphocytes were utilized to target multiple myeloma (MM) tumor cells (2015). The
lymphocytes were set to recognize the NY-ESO-1 and LAGE-1 antigens. Through past
experimentation, it was discovered that approximately 60% of advanced MM cells express the
NY-ESO-1 protein antigen, an immunogenic cancer-testis antigen, on their MHC class 1
molecules. This antigen has previously been shown to produce spontaneous and vaccine-induced
immunity making it a good target for this therapy. Therefore, Rapaport et al. hypothesized that a
TCR engineered to recognize these antigens could induce cell death in the targeted cells.
To generate T lymphocytes capable of binding these targeted antigens, the immune cells
were injected with an HIV-1 derived lentiviral vector (Rapaport et al., 2015). The vector was

T CELL THERAPY

15

produced by addition of a transfer vector expressed on four plasmids and other components
responsible for the insertion of the donor sequence into the host genome. Following this, the T
lymphocytes were edited by transformation with the generated lentiviral vector and re-inserted in
vivo. The lymphocytes were allowed to interact with host tissues and analyzed incrementally
after implantation. To study the effect of the TCR lymphocytes, samples were taken from bone
marrow and peripheral blood tissues. For example, after running tests such as Q-PCR analysis
and TCR clonotype analysis, it was determined that a statistically significant number of T
lymphocytes expressed the desired engineered TCR. In conclusion, the research team found that
NY-ESOc259 TCR-engineered T-cells generated ex-vivo did not experience rejection from host
tissues or stimulate significant negative side effects. Further, they were found to expand in vivo,
traffic well to the tumor site, and show persistent, on-target anti-tumor activity. This study
provides significant proof of the potential effectiveness of this type of treatment model.
Going further, significant progress has also been seen in the treatment of other solid
tumor types. For example, the MART-1 antigen has been targeted in the treatment of metastatic
melanoma. In a study of 20 people, the average person experienced a 30% objective antitumor
response. Even more impressive, researchers studying this disease and synovial cell carcinoma
attempted treatment through targeting the NY-ESO-1 antigen. In this study of 17 people, two
saw complete remission while one saw partial remission. Additional studies have also revealed
promise in targeting leukemia and lymphoma. By generating proprietary antibody-TCR
(AbTCR) T cells, these hematological malignancies have begun to be addressed.
Advantages and Challenges
TCR-T cell therapy has several advantages over traditional cancer therapy techniques.
For example, any antigen presented on MHC molecules can induce an antitumor response in the
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engineered T lymphocytes. This provides a wide range of targets for this therapy technique in
comparison to the hallmark of proliferation frequently targeted by traditional methods.
Additionally, because the lymphocytes maintain all the TCR auxiliary molecules of signal
transduction, they are capable of full activation by antigen recognition. This retention of function
allows engineered T lymphocytes to generate potent anti-tumor effects surpassing that of
conventional techniques.
Unfortunately, TCR-T cell therapy also has a certain number of challenges that limit the
application of this technique to cancer treatment. For example, because it is using a TCR to
recognize cancerous antigens, the antigens must be processed endogenously and presented on
MHC class 1 molecules. This excludes any antigen presented either without an MHC or on an
MHC class 2 molecule on the target cell’s membrane This is known as MHC restriction as
antigen recognition is restricted only to those capable of presentation on the correct MHCs. This
poses a great obstacle to the application of the disease as the number of presented cancerous
antigens is limited. Additionally, there is a risk of host vs. graft disease. Essentially, the grafted
tissue, in this case reintroduced T cells, can attack the normal host tissue. By altering the affinity
of TCRs towards self-MHC molecules, dangerous cross-reactivity can occur (Rath & Arber,
2020). Instead of generating a killing response against the targeted antigen, physiologically
normal antigens are targeted and activate the altered T lymphocyte. This can lead to lethal
reactions in the patient. Finally, the infiltrating TCR-T cells must overcome the tumor
microenvironment (TME). While altered to recognize cancerous antigens, the TCR lymphocytes
retain the limitations to the TME as unaltered T lymphocytes. Each TCR lymphocyte encounters
the dense, physical barrier of tumor-associated cells surrounding the area obstructing invasion.
Anergy is also encouraged by cytokines such as IL-10 and inhibitory receptor binding such as
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CTLA-4 and PD-1. Additionally, the tumor lacks homing factors specific to T lymphocytes,
which leads to a lack of directed movement to the tumor and a subsequent lack of tumor antigen
detection. To further inhibit T lymphocytes, the TME also recruits additional
immunosuppressive cells such as tumor-associated macrophages and myeloid derived suppressor
cells.
CAR-T Cell Therapy
CAR-T cell therapy addresses the problem of cancer similarly to TCR-T cell therapy;
however, significant differences exist in the recognition and activation of the T lymphocyte
(Wang et al., 2017). The main difference lies in the core of the CAR-T cell: the chimeric antigen
receptor. This receptor complex allows the T lymphocyte to recognize any antigenic protein
located on the surface of the plasma membrane of the target cell without MHC restriction.
Essentially, the CAR bypasses the need for the use of the TCR complex. From here, a CAR-T
cell is placed into one of three classes (or generations) based on its components (Barrett et al.,
2014). For the latest generation, it is routinely comprised of the single-chain variable fragment
domain (scFv) of the targeted antibody for antibody recognition and intracellular signaling
domains including that of CD3z for signaling and T lymphocyte activation (Wang et al., 2017).
The CAR is also complexed with several costimulatory CDs such as CD28, CD 137, or CD134
to help achieve activation. By including these components, the CAR acts to replace the TCR,
excluding the need for the normally required MHC/TCR stimulatory interaction. With this in
mind, to develop a CAR-T cell, an antigen on the surface of the targeted cell must be chosen for
CAR development. Once picked, the CAR complex is converted into its corresponding genetic
code and inserted into the T lymphocyte genome ex vivo via genetic editing technology. After
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testing for successful transfection and safety, like TCR-T cells, they are transferred back to the
body for immunogenic activity.
Clinical Manifestations
Large potential for CAR-T cell therapy has been witnessed by researchers in a wide
variety of cancer treatments. One of the greatest advancements has been revealed in the
treatment of B cell malignancies. For example, one study by Ying et al. (2019) delved into the
possibility of treating refractory B cell lymphoma. It has been previously shown that B cells
express CD19 throughout development and are present on the majority of cancerous B cells.
Therefore, anti-CD19 CAR-T cells (CART-19) targeting the CD19 immunoglobulin domain are
highly utilized in B lymphocyte cancer immunotherapy. Specifically, the study by Ying et al.
chose to target B cell lymphoma by generating a new species of CART-19 lymphocytes known
as CD19-BBz(86). This species was adapted from the previous CD19-BBz species which
possessed an scFv from the FMC63 antigen, several costimulatory domains including CD3
signaling domains, and CD8α transmembrane and linking domains. To improve its safety, the
CD8α domains were genetically altered resulting in the CD19-BBz(86) variant. This CART-19
species was then packaged into a lentiviral vector for transfection of T lymphocytes. These
CART-19 cells were found to produce cytokines at decreased levels, express anti-apoptotic
molecules at higher levels, and proliferate slower than the prototype CD19-BBz CAR T cells
while retaining potent cytolytic activity.
After this discovery, the newly engineered CART-19 cells were infused to 25 patients
exhibiting refractory B cell lymphoma. Of the 25 patients, six received a low dose, eight received
a medium dose, and eleven received a high dose. Three of the patients receiving a low dose
manifested a treatment response with two attaining partial remission and one complete
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remission. In addition, three of the medium dose patients attained partial remission. Remarkably,
complete remission was seen in six of the high dose patients while two achieved partial
remission. The results of the study revealed an incredible new avenue for the treatment of this
disease.
Another disease seeing marvelous improvement through CAR-T cell therapy is acute
lymphoblastic leukemia (ALL) (Maude et al., 2014). Similar to B cell lymphoma, the researchers
studying ALL engineered T lymphocytes to recognize CD19+ cancerous B cells. By generating a
CD19-BBz variant capable of recognizing ALL cells, the researchers were able to synthesize
CART-19 cells capable of fighting the disease. Again, like the study by Ying et al., the cells
were engineered via a lentiviral vector and returned to the host for immunogenic activity.
Incredibly, one month after infusion twenty-seven of the thirty participants were in complete
remission. Unfortunately, only half remained in full remission at six months after treatment.
While CAR-T cell therapy has shown incredible potential for cancer treatment, advances are
required for remission to be achieved more safely and to be applied to a greater number of
people.
Barriers
One of the greatest advantages to CAR-T cell therapy is its ability to target non-HLA
presented peptide antigens (Zhao & Cao, 2019). Often, cancerous cells downregulate MHC
molecules to reduce the presentation of cancerous antigens to T lymphocytes. CAR-T cells are
successfully able to circumvent this strategy. A subsequent advantage is also found in that any
antigen found on the cell's surface is viable for targeting. This presents a large range of targetable
antigens for use in CAR-T cell therapy.
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Unfortunately, while this treatment shows great promise for the targeting of cancerous
cells, several barriers stand in the way of further application in the field. One of the largest
barriers is found in cytokine release storms (CRSs) as it is the most widely reported adverse side
effect of CAR-T cell therapy (Zhao & Cao, 2019). Essentially, CRS is the release of a significant
amount of inflammatory cytokines from the interaction of CAR-T cells with their environment.
However, the cytokines do not originate solely from the engineered lymphocytes. Myeloid cells
such as monocytes, macrophages, and dendritic cells also synthesize and release cytokines,
which add to those caused by the engineered T lymphocytes. Ultimately, CRS can result in lifethreatening complications from the accumulation of dangerous symptoms such as long term
fever, hypotension, dyspnea, and organ problems. Additionally, patients undergoing CAR-T cell
therapy risk neurotoxicity. Overall, 40% of those treated experience this dangerous complication.
Symptoms include decreased consciousness, confusion, seizures, and brain edema. While it can
be paired with CRS, this side effect can be found alone.
Another significant challenge associated with CAR-T cell treatment is on-target/offtumor toxicity (Zhao & Cao, 2019). When selecting antigens for CAR recognition, the ideal
would be to only select those expressed on the surface of cancerous cells; unfortunately, the
majority of cancerous antigens are not specific to the diseased cells. Due to this lack of
specificity, there is a high difficulty associated with identifying antigens exclusively expressed
on cancerous cells. Subsequently, most CAR-T treatments possess at least small amounts of ontarget antigen recognition on off-target cells. This aspect of the treatment leads to most of the
side effects seen in CAR-T cell therapy.
Another considerable challenge facing CAR-T cell therapy is that of solid tumor
treatment (Watanabe & Nishikawa, 2021). Incredible potential has been seen in the treatment of
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hematological tumors; however, solid tumors have shown less promise. Clinical trials often
result in unsatisfactory results compared to blood related malignancies. This is due to several
factors including the type of antigens found on solid tumors and the accumulation of
immunosuppressive cells. Unfortunately, while the antigens presented on hematological tumors
are tissue specific, that is not the case with solid tumors. Often, these antigens are also expressed
on normally functioning tissues making it hard to find antigens for targeting by the CARs. Going
further, even after targeting specific solid tumor antigens, as in TCR-T cell therapy, the TME of
the solid tumor actively counteracts the effects of the T lymphocytes.
Finally, CAR-T cell therapy is incredibly expensive (Zhao & Cao, 2019). In 2019, only
two therapy options were available for patients willing to test the experimental treatment. The
more costly option equated to an average of $510,963 per patient while the less expensive cost
an average of $402,647. If no effect was seen after one month, the fees were waived; however, if
an effect was seen, the price was high. Unfortunately, after nearly three years of research, the
price still hovers around $400,000 excluding inpatient hospitalization costs and any treatment
costs resulting from complications (Bhaskar et al., 2021). Going further, not only is the treatment
costly, but it also requires a significant amount of time (Zhao & Cao, 2019). It takes anywhere
from half a month to one month to generate specific CAR-T cells for any one patient. This large
amount of time carries the ability to prevent patients from receiving treatment in a time-efficient
manner. Considerable challenges face the development and applicability of this treatment.
TCR-T vs CAR-T Cell Therapy
Both treatment options possess associated pros and cons, some shared while others
specific (Zhao & Cao, 2019). For example, TCR-T cells can target not only cell-surface antigens
but also intracellular derived antigens. Through this capability, antigens such as NY-ESO-1 are
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utilized by TCR-T cells to target cancerous cells in a way CAR-T cells cannot. Unfortunately,
the antigens must be presented by MHC molecules targetable by the TCR. This largely limits the
number of targetable antigens, especially if the cancerous cell downregulates or mutates its MHC
molecules. A plateau has been seen in recent years in TCR-T cell therapy due to the limiting
nature of MHC restriction associated with this technique. Until additional intracellular cancer
antigens are identified, this treatment method will remain limited in its scope of treatment.
Contrarily, while the CAR component of CAR-T cells cannot target intracellularly
derived antigens, it can target any cell surface antigen (Zhao & Cao, 2019). As previously stated,
the CAR is not inhibited by MHC restriction. This adds an ability to the CAR repertoire that the
TCR does not possess. Additionally, since TCR-T cell therapy relies on MHC presentation, it is
also restricted to recognizing peptide antigens. This is another restriction bypassed by the CAR
model. Any antigen, regardless of molecular composition, can be targeted by the CAR-T cell.
Because of these properties, the CAR possesses a much broader range of targetable antigens.
However, while virtually any cell can be targeted, antigens must be identified that are expressed
solely on the cancerous cell. Without selective cancerous antigenic expression, the CAR-T cell
would stimulate cell death in normal host tissue, causing more harm than good. Additionally, the
dosage required for CAR-T cell therapy is significantly less than that required for TCR-T cell
therapy due to the CAR’s high specificity, clear target, and lack of MHC restriction.
Continuing, both CAR-T and TCR-T cell therapy experience similar setbacks in their
respective treatment models (Zhao & Cao, 2019). One of the largest examples is the barrier
associated with the TME in solid tumors (Watanabe & Nishikawa, 2021). Both models have
shown promise in the treatment of hematological tumors, with great success shown in CAR-T
models specifically; unfortunately, the immunosuppressive nature of the TME found in solid
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tumors has yielded challenges in the function, infiltration, and survival of T lymphocytes. While
both CAR-T and TCR-T cells possess the ability to target specific antigens associated with the
cancerous tissue, the lymphocytes often encounter resistance discouraging proliferation and
activation. From this action of the TME, both therapy techniques have encountered significant
resistance in the treatment of solid tumors. Both have shown great promise in the treatment of
hematological malignancies; however, strides need to be made in this area for either treatment to
successfully address solid tumors.
Future Directions
CRS
Both CAR-T and TCR-T cell therapy models have revealed promise in their respective
treatments; however, to broaden their scope, improvements must be made (Zhao & Cao, 2019).
For example, by addressing the problem of CRS, CAR-T cell therapy could be advanced. As
previously stated, the impact of CAR-T cells on the body often initiates the release of proinflammatory cytokines, primarily IL-6, which result in potentially life-threatening symptoms. If
CRS was reduced or negated, the safety of CAR-T cell therapy would be greatly improved.
Currently, treatment options for those threatened with CRS are limited to “intensive medical
care, including the use of ventilators, drugs to increase blood pressure, and antiepilepsy drugs,”
(Zhao & Cao, 2019, p. 6). Additionally, an IL-6 inhibitor drug has been approved by the FDA
known as tocilizumab. This drug has begun to be used widely in the effort to suppress the
inflammatory immune response and has been shown repeatedly to reduce CRS (Brudno &
Kochenderfer, 2019). Further, the use of corticosteroids in tandem with tocilizumab has resulted
in even greater immune suppression. Unfortunately, corticosteroids can also have the effect of T
lymphocyte impairment, so their use is reserved for high grade CRS. Additionally, the use of
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these drugs does not always abolish CRS, only serving to lessen the severity of symptoms. The
development of next generation CAR-T cells could address this problem at its source. By
generating lymphocytes capable of secreting anti-inflammatory cytokines or possessing
additional co-stimulatory domains, the cells inducing the inflammatory response could be trained
to avoid this complication.
CRISPR/Cas9
Another avenue in which improvement can be made is that of the process of insertion of
genetic information (Ren & Zhao, 2017). Currently, the process of inserting large DNA
sequences encoding CARs requires a viral vector and is preferred in TCR editing. Unfortunately,
these vectors, as previously stated, are not site-specific. This limitation can lead to ineffective or
disruptive gene insertion especially when the donor information is inserted into essential DNA
sequences. To address this, researchers have searched for ways in which to insert genetic
information via homology directed repair (HDR). One of the primary methods for doing so is
through CRISPR/Cas9. As previously stated, by adding the sgRNA guide sequences and Cas9
endonuclease to the vector, specific sites can be targeted to eliminate the random insertion effect
of lentiviral or adenoviral vectors. Unfortunately, advances need to be made in the applicability
of this technique. For example, the use of CRISPR/Cas9 requires reagents that can be highly
toxic to the T lymphocytes targeted for transformation. In addition, this technique experiences
difficulties when inserting large DNA sequences. With these specific avenues addressed,
successful on-target DNA insertion could be more easily achieved.
TME
A further direction holding potential for improving T lymphocyte activity is found in
addressing the TME (Arina et al., 2016). A significant challenge to both CAR-T and TCR-T cell
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therapy is that of the environment surrounding solid tumors. As previously described, it actively
inhibits the proliferation and activation of T lymphocytes; therefore, neutralizing its effects could
greatly improve the efficacy of both T cell therapy strategies. Although improvements need to be
made in each, a variety of methods have been developed to decrease the effects of the TME.
One of these is the generation of tertiary lymphoid structures (TLS) in the proximity of
the TME (Arina et al., 2016). Similar in composition to lymph nodes, TLSs commonly develop
in the presence of chronic inflammation or cancer to support and promote lymphocyte activity in
these regions. The presence of TLSs has been correlated with a stronger immune response to
both colorectal and lung cancer. In theory, by promoting the growth of these lymphoid tissues,
the persistence of T lymphocytes would be encouraged in these sites. A similar study on LIGHT
(TNFSF14), a signaling molecule in the TNF family, revealed results in favor of this theoretical
treatment. LIGHT can bind to HVEM on T cells as a costimulatory molecule and lymphotoxin-β
receptor (LTβR) on non-lymphoid cells. LTβR results in the organization and maintenance of
lymphoid tissues such as lymph nodes through its expression. When LIGHT was overexpressed
in cancer patients, T lymphocyte infiltration was greatly improved in their TMEs providing
evidence for the validity of the TLS approach. Further research in this area could serve to
advance this theoretical treatment option.
Additionally, furthering the understanding of signaling molecules such as chemokines
and cytokines contributing to both immunosuppression and stimulation could help decrease the
effects of the TME (Arina et al., 2016). For example, through the expression of the CCL2
chemokine tumor-associated macrophages (TAMs) are recruited to the cancerous site to maintain
the suppressive nature of the TME. Similarly, the CSF-1 cytokine is an important signaling
molecule in the recruitment of immunosuppressive monocytes. If the cytokine and chemokine
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milieu surrounding the TME were altered, its immunosuppressive nature could be greatly
decreased. One way to accomplish this would be to generate T lymphocytes with the ability to
secrete cytokines and chemokines promoting their infiltration and proliferation. One study
attempted this by generating CAR-T lymphocytes engineered to produce IL-7 and CCL19
(Watanabe & Nishikawa, 2021). These are commonly seen in the maintenance of T lymphocyte
zones in lymph nodes via T-zone fibroblast reticular cells secretion. The modified cells showed
an increased anti-tumor effect that could be leveraged for future treatment techniques. Further
studies could reveal improved treatment options for both CAR-T and TCR-T cell therapy.
Conclusion
To conclude, T cell therapy is an emerging therapeutic option for patients afflicted by
many cancer types. By manipulating the natural defenses of the body, clinicians can target
specific cancerous tissues without the undesired effect of killing healthy, bystander cells.
Unfortunately, significant challenges such as CRS, the TME, and high cost stand in the way of
widespread application of this technique, especially in the treatment of solid tumors. However, in
recent years, great progress has been seen. With continued effort, T cell therapy could be applied
to larger populations of people in the pursuit of curing cancer.

T CELL THERAPY

27
References

Arina, A., Corrales, L., & Bronte, V. (2016). Enhancing T cell therapy by overcoming the
immunosuppressive tumor microenvironment. Seminars in Immunology, 28(1), 54–63.
https://doi.org/10.1016/j.smim.2016.01.002
Barrett, D. M., Singh, N., Porter, D. L., Grupp, S. A., & June, C. H. (2014). Chimeric antigen
receptor therapy for cancer. Annual Review of Medicine, 65(1), 333-347.
doi:10.1146/annurev-med-060512-150254
Beissert, S., Schwarz, A., & Schwarz, T. (2006). Regulatory T cells. Journal of Investigative
Dermatology, 126(1), 15–24. https://doi.org/10.1038/sj.jid.5700004
Bertoletti, A., & Tan, A. T. (2020). Challenges of CAR- and TCR-T cell–based therapy for
chronic infections Rockefeller University Press. doi:10.1084/jem.20191663
Bhaskar, S. T., Dholaria, B. R., Sengsayadeth, S. M., Savani, B. N., & Oluwole, O. O. (2021).
Role of bridging therapy during chimeric antigen receptor T cell therapy. EJHaem, 3(S1),
39–45. https://doi.org/10.1002/jha2.335
Blüthmann, H., Kisielow, P., Uematsu, Y., Malissen, M., Krimpenfort, P., Berns, A., von
Boehmer, H., & Steinmetz, M. (1988). T-cell-specific deletion of T-cell receptor transgenes
allows functional rearrangement of endogenous α- and β-genes. Nature, 334(6178), 156–
159. https://doi.org/10.1038/334156a0
Brudno, J. N., & Kochenderfer, J. N. (2019). Recent advances in car T-cell toxicity:
Mechanisms, manifestations and management. Blood Reviews, 34, 45–55.
https://doi.org/10.1016/j.blre.2018.11.002
Chaplin, D. D. (2010). Overview of the immune response. Journal of Allergy and Clinical
Immunology, 125(2), S3-S23. doi:10.1016/j.jaci.2009.12.980

T CELL THERAPY

28

Chi, S., Weiss, A., & Wang, H. (2016). A CRISPR-based toolbox for studying T cell signal
transduction. BioMed Research International, 2016, 5052369-10.
doi:10.1155/2016/5052369
Duong, M. N., Erdes, E., Hebeisen, M., & Rufer, N. (2019). Chronic TCR-MHC (self)interactions limit the functional potential of TCR affinity-increased CD8 T lymphocytes.
Journal for Immunotherapy of Cancer, 7(1), 284. doi:10.1186/s40425-019-0773-z
Hanahan, D., & Weinberg, R. (2011). Hallmarks of cancer: The next generation. Cell
(Cambridge), 144(5), 646-674. doi:10.1016/j.cell.2011.02.013
Hegde, P. S., & Chen, D. S. (2020). Top 10 challenges in cancer immunotherapy. Immunity
(Cambridge, Mass.), 52(1), 17-35. doi:10.1016/j.immuni.2019.12.011
Huseby, E. S., White, J., Crawford, F., Vass, T., Becker, D., Pinilla, C., Marrack, P., Kappler, J.
W. (2005). How the T cell repertoire becomes peptide and MHC specific. Cell (Cambridge),
122(2), 247-260. doi:10.1016/j.cell.2005.05.013
June, C. H., O’Conner R. S., Kawalekar, O. U., Ghassemi, S., & Milone, M. C.CAR T cell
immunotherapy for human cancer
Cong, L., Ran, F. A., Cox, D., Lin, S., Barretto, R., Habib, N., Hsu, P. D., Wu, X., Jiang, W.,
Marraffini, L. A., Zhang, F. (2013). Multiplex genome engineering using CRISPR/cas
systems. Science (American Association for the Advancement of Science), 339(6121), 819823. doi:10.1126/science.1231143
Maude, S. L., Frey, N., Shaw, P. A., Aplenc, R., Barrett, D. M., Bunin, N. J., Chew, A.,
Gonzalez, V. E., Zheng, Z., Lacey, S. F., Mahnke, Y. D., Melenhorst, J. J., Rheingold, S. R.,
Shen, A., Teachey, D. T., Levine, B. L., June, C. H., Porter, D. L., Grupp, S. A. (2014).

T CELL THERAPY

29

Chimeric antigen receptor T cells for sustained remissions in leukemia. The New England
Journal of Medicine, 371(16), 1507-1517. doi:10.1056/NEJMoa1407222
Milone, M. C., & O’Doherty, U. (2018). Clinical use of lentiviral vectors. Leukemia, 32(7),
1529–1541. https://doi.org/10.1038/s41375-018-0106-0
Parker, D. C. (1993). T cell-dependent B cell activation. Annual Review of lmmunology, 11, 33160.
Passos, G. A., Speck-Hernandez, C. A., Assis, A. F., & Mendes-da-Cruz, D. A. (2017). Update
on Aire and thymic negative selection. Immunology, 153(1), 10–20.
https://doi.org/10.1111/imm.12831
Rath, J. A., & Arber, C. (2020). Engineering strategies to enhance TCR-based adoptive T cell
therapy. Cells, 9(6), 1485. https://doi.org/10.3390/cells9061485
Rapoport, A. P., Stadtmauer, E. A., Binder-Scholl, G. K., Goloubeva, O., Vogl, D. T., Lacey, S.
F., Badros, A. Z., Garfall, A., Weiss, B., Finklestein, J., Kulikovskaya, I., Sinha, S. K.,
Kronsberg, S., Gupta, M., Bond, S., Melchiori, L., Brewer, J. E., Bennett, A. D., Gerry, A.
B., … June, C. H. (2015). NY-ESO-1–specific TCR–engineered T cells mediate sustained
antigen-specific antitumor effects in myeloma. Nature Medicine, 21(8), 914–921.
https://doi.org/10.1038/nm.3910
Redmond, W. L., Wei, C.-H., Kreuwel, H. T., & Sherman, L. A. (2008). The apoptotic pathway
contributing to the deletion of naive CD8 T cells during the induction of peripheral tolerance
to a cross-presented self-antigen. The Journal of Immunology, 180(8), 5275–5282.
https://doi.org/10.4049/jimmunol.180.8.5275
Ren, J., & Zhao, Y. (2017). Advancing chimeric antigen receptor T cell therapy with
CRISPR/Cas9. Protein & Cell, 8(9), 634-643. doi:10.1007/s13238-017-0410-x

T CELL THERAPY

30

Roth, D. B. (2014). V(D)J recombination: Mechanism, errors, and fidelity. Microbiology
Spectrum, 2(6). https://doi.org/10.1128/microbiolspec.mdna3-0041-2014
Sadelain, M., Brentjens, R., & Rivière, I. (2013). The basic principles of chimeric antigen
receptor design. Cancer Discovery, 3(4), 388-398. doi:10.1158/2159-8290.CD-12-0548
Siegel, R. L., Miller, K. D., & Jemal, A. (2016). Cancer statistics, 2016. CA: A Cancer Journal
for Clinicians, 66(1), 7-30. doi:10.3322/caac.21332
Smith-Garvin, J. E., Koretzky, G. A., & Jordan, M. S. (2009). T cell activation. Annual Review
of Immunology, 27(1), 591-619. doi:10.1146/annurev.immunol.021908.132706
Sykulev, Y., Joo, M., Vturina, I., Tsomides, T. J., & Eisen, H. N. (1996). Evidence that a single
Peptide–MHC complex on a target cell can elicit a cytolytic T cell response. Immunity
(Cambridge, Mass.), 4(6), 565-571. doi:10.1016/S1074-7613(00)80483-5
Wang, Z., Wu, Z., Liu, Y., & Han, W. (2017). New development in CAR-T cell therapy. Journal
of Hematology and Oncology, 10(1), 53. doi:10.1186/s13045-017-0423-1
Watanabe, K., & Nishikawa, H. (2021). Engineering strategies for broad application of TCR-Tand car-T-cell therapies. International Immunology, 33(11), 551–562.
https://doi.org/10.1093/intimm/dxab052
Ying, Z., Huang, X. F., Xiang, X., Liu, Y., Kang, X., Song, Y., Guo, X., Liu, H., Ding, N.,
Zhang, T., Duan, P., Lin, Y., Zheng, W., Wang, X., Lin, N., Tu, M., Xie, Y., Zhang, C., Liu,
W., … Chen, S.-Y. (2019). A safe and potent anti-cd19 car T cell therapy. Nature Medicine,
25(6), 947–953. https://doi.org/10.1038/s41591-019-0421-7
Zhan, T., Rindtorff, N., Betge, J., Ebert, M. P., & Boutros, M. (2019). CRISPR/Cas9 for cancer
research and therapy. Seminars in Cancer Biology, 55, 106-119.
doi:10.1016/j.semcancer.2018.04.001

T CELL THERAPY
Zhao, L., & Cao, Y. J. (2019). Engineered T cell therapy for cancer in the clinic. Frontiers in
Immunology, 10, 2250. doi:10.3389/fimmu.2019.02250

31

